Martínez A S, Domené H M, Ropelato M G, Jasper H G, Pennisi P A, Escobar M E, Heinrich J J
División de Endocrinología, Centro de Investigaciones Endocrinológicas, Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina.
J Clin Endocrinol Metab. 2000 Nov;85(11):4168-72. doi: 10.1210/jcem.85.11.6928.
We have studied the effect of estradiol (E2) on the GH-insulin-like growth factor (GH-IGF) axis in 15 prepubertal GH deficiency (GHD) children and 44 prepubertal or early pubertal children with idiopathic short stature (SS). All of them received a daily dose of micronized E2 (1 or 2 mg) or placebo, for 3 days, before a sequential arginine-clonidine test. In SS children, GH maximal responses were 17.8+/-10.9 on placebo and 27.9+/-14.5 microg/L on estrogen (P < 0.0001). The lower 95% confidence limits for GH maximal response changed from 3.7 microg/L (without E2) to 8.3 microg/L (on E2). In GHD children, no significant stimulatory effect of estrogen on GH levels was observed. After placebo, a cut-off limit of 3.7 microg/L (the lower 95% confidence interval limit) resulted in 73% sensitivity, 95% specificity, and an overall 90% diagnostic efficiency. After E2, a cut-off limit of 8.3 microg/L resulted in a sensitivity of 87%, a specificity of 98%, and a diagnostic efficiency of 95%. After placebo, 68% of SS showed normal IGF-I levels, and the mean did not change on E2 (13.7+/-6.3 vs. 14.3+/-6.8 nmol/L, not significant). In 93% of SS, IGF binding protein (IGFBP)-3 levels were normal during placebo. On E2, mean IGFBP-3 did not change (2.63+/-0.70 vs. 2.70+/-0.70 mg/L, not significant). In 14 of 15 GHD patients, IGF-I values were below normal on placebo, and the mean of the group did not change after E2. During placebo, 13 of 15 GHD children presented low IGFBP-3 values. During E2, there was a small significant increase in IGFBP-3 values (1.06+/-0.58 vs. 1.20+/-0.69 mg/L, P < 0.02). The highest diagnostic efficiencies for IGF-I and IGFBP-3 were observed during placebo (75% and 91%, respectively). We conclude that GH stimulation tests after E2 priming had the highest diagnostic efficiency. Our findings suggest that the effect of estrogen priming on GH stimulated levels, by reducing the number of false nonresponders, might be useful to better discriminate between normal and abnormal GH status in SS children.
我们研究了雌二醇(E2)对15名青春期前生长激素缺乏(GHD)儿童和44名青春期前或青春期早期特发性矮小(SS)儿童的生长激素-胰岛素样生长因子(GH-IGF)轴的影响。在进行精氨酸-可乐定序贯试验前,所有儿童均每日服用微粒化E2(1或2毫克)或安慰剂,持续3天。在SS儿童中,安慰剂组的生长激素最大反应为17.8±10.9,雌激素组为27.9±14.5微克/升(P<0.0001)。生长激素最大反应的95%置信下限从(无E2时)3.7微克/升变为(使用E2时)8.3微克/升。在GHD儿童中,未观察到雌激素对生长激素水平有显著刺激作用。服用安慰剂后,以3.7微克/升(95%置信区间下限)为临界值,敏感性为73%,特异性为95%,总体诊断效率为90%。使用E2后,以8.3微克/升为临界值,敏感性为87%,特异性为98%,诊断效率为95%。服用安慰剂后,68%的SS儿童胰岛素样生长因子-I(IGF-I)水平正常,使用E2后平均值未改变(13.7±6.3对14.3±6.8纳摩尔/升,无显著差异)。在93%的SS儿童中,安慰剂期间胰岛素样生长因子结合蛋白(IGFBP)-3水平正常。使用E2后,IGFBP-3平均值未改变(2.63±0.70对2.70±0.70毫克/升,无显著差异)。15名GHD患者中有14名在服用安慰剂时IGF-I值低于正常水平,使用E2后该组平均值未改变。服用安慰剂期间,15名GHD儿童中有13名IGFBP-3值较低。使用E2期间,IGFBP-3值有小幅显著升高(1.06±0.58对1.20±0.69毫克/升,P<0.02)。IGF-I和IGFBP-3的最高诊断效率在服用安慰剂期间观察到(分别为75%和91%)。我们得出结论,E2预处理后的生长激素刺激试验具有最高的诊断效率。我们的研究结果表明,雌激素预处理对生长激素刺激水平的影响,通过减少假无反应者的数量,可能有助于更好地区分SS儿童的正常和异常生长激素状态。